{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-055915","form_type":"8-K","ticker":null,"cik":"0001741830","company_name":"Kronos Bio, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.533735+00:00","generated_at":"2026-05-19T01:36:32.256220+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kronos Bio acquired by Concentra Biosciences for $0.57/share plus CVR; delisting effective","bullets":["Tender offer closed June 18 with 44.5M shares (72.9% outstanding) tendered; merger completed June 20.","Shareholders receive $0.57 cash per share plus one non-transferable contingent value right (CVR) per share.","All conditions to tender offer and merger satisfied; shares to be delisted from Nasdaq and deregistered.","Board of directors resigned; new directors and officers from Concentra Merger Sub appointed (CEO Kevin Tang).","Company became wholly owned subsidiary of Concentra Biosciences; articles and bylaws amended."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-055915","json":"https://secwatch.observer/filing/0001213900-25-055915.json","markdown":"https://secwatch.observer/filing/0001213900-25-055915.md","text":"https://secwatch.observer/filing/0001213900-25-055915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/ea0246047-8k_kronos.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:36:32.256220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"076f100389","claim":"Kevin Tang was appointed as Chief Executive Officer at Kronos Bio, Inc..","evidence_excerpt":"The executive officers of Merger Sub immediately prior to the Effective Time were: (i) Mr. Tang, Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"1576b515aa","claim":"Roger Dansey resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1bfea51de7","claim":"Katherine Vega Stultz resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1c2cca0d66","claim":"Taiyin Yang resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2ec0187afb","claim":"Joshua Kazam resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6d6b302d4f","claim":"Norbert Bischofberger resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"76f5e94224","claim":"David M. Tanen resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7835ec5c9a","claim":"Elena Ridloff resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7aab0d5d1b","claim":"Deborah Knobelman resigned as other_named_officer at Kronos Bio, Inc..","evidence_excerpt":"Dr. Deborah Knobelman resigned from her position as an officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"9839a91edc","claim":"Roshawn Blunt resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9d29b761d5","claim":"Kevin Tang was appointed as Director at Kronos Bio, Inc..","evidence_excerpt":"The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a8b0ce1bfe","claim":"Arie Belldegrun resigned as Director at Kronos Bio, Inc..","evidence_excerpt":"at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e1535f5f1d4eb2e329c0e3ee512428bb2f91410","claim":"Kronos Bio, Inc. underwent a change of control involving Concentra Biosciences, LLC for $0.57 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2025-06-20).","evidence_excerpt":"2025, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), in exchange for (i) $0.57 in cash per Share (the “Cash Amount”); plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR,” and each CVR together with the Cash Amount, the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Concentra Biosciences, LLC"},{"label":"Consideration","value":"$0.57 in cash per Share plus one non-transferable contractual contingent value right per Share"},{"label":"Closing","value":"2025-06-20"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}